Adalvo signs licence deal with EQL Pharma for Mellozzan
Pharmaceutical Technology
MAY 25, 2023
Adalvo has entered a strategic licensing agreement with Swiss pharmaceutical company EQL Pharma for Mellozzan (melatonin) outside Europe and the US. Mellozzan contains the sleep hormone melatonin and is indicated for use in children with attention deficit hyperactivity disorder (ADHD) and sleep difficulties.
Let's personalize your content